Abstract Background: Psilocybin, the primary psychoactive component of psychedelic ‘magic mushrooms’, may have potential for treating depressive symptoms, and consequent applications for bipolar disorder
There has been an increase in research on the topic of psychedelic substances and their effects as treatment options in neuropsychiatric conditions. Psilocybin is a
Abstract Rationale In recent years, psychedelic substances with serotonergic mechanisms have accumulated substantial evidence that they may provide therapeutic benefits for people suffering with
Abstract Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety
ABSTRACT Borderline Personality Disorder (BPD) is a severe psychiatric disorder characterized by behavioral dysregulation, emotion dysregulation, disturbances in self-identity, and social functioning. Despite the
ABSTRACT Research on the therapeutic potential of psychedelic substances is expanding. A limitation within this field is the unpredictability of individual responses to psychedelics.
Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression suggest modest efficacy but raise concerns about potential for serious adverse effects. The
Abstract Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean
Abstract Acute adverse psychological reactions to classic hallucinogens (“bad trips”, or “challenging experiences”), while usually benign with proper screening, preparation, and support in controlled
©2023 Unlimited Sciences. All rights reserved.
Our newsletter is meant to provide you with the latest news in psychedelic research, inform you about our work, and inspire you with compelling stories from all over the world about the power of psychedelics.
